Next Article in Journal
The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo
Next Article in Special Issue
α6β4 Integrin Genetic Variations (A380T and R1281W) and Breast Cancer Risk in an Argentinian Population
Previous Article in Journal
A Genomics-Based Model for Prediction of Severe Bioprosthetic Mitral Valve Calcification
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(9), 1432; doi:10.3390/ijms17091432

β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer

1
Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 807 Kaohsiung, Taiwan
2
Department of Pathology, Faculty of Medicine, Collage of Medicine, Kaohsiung Medical University, 807 Kaohsiung, Taiwan
3
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 807 Kaohsiung, Taiwan
4
Cancer Center, Kaohsiung Medical University Hospital, 807 Kaohsiung, Taiwan
5
Graduate Institute of Clinical Medicine, Kaohsiung Medical University, 807 Kaohsiung, Taiwan
6
National Institute of Cancer Research, National Health Research Institutes, 704 Tainan, Taiwan
7
Research Center for Environmental Medicine, Kaohsiung Medical University, 807 Kaohsiung, Taiwan
*
Authors to whom correspondence should be addressed.
Academic Editors: Anthony Lemarié and Sylvie Monferran
Received: 20 July 2016 / Revised: 3 August 2016 / Accepted: 23 August 2016 / Published: 31 August 2016
(This article belongs to the Special Issue Integrins in Cancer)
View Full-Text   |   Download PDF [5955 KB, uploaded 31 August 2016]   |  

Abstract

Triple negative breast cancer (TNBC) displays higher risk of recurrence and distant metastasis. Due to absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), TNBC lacks clinically established targeted therapies. Therefore, understanding of the mechanism underlying the aggressive behaviors of TNBC is required for the design of individualized strategies and the elongation of overall survival duration. Here, we supported a positive correlation between β1 integrin and malignant behaviors such as cell migration, invasion, and drug resistance. We found that silencing of β1 integrin inhibited cell migration, invasion, and increased the sensitivity to anti-cancer drug. In contrast, activation of β1 integrin increased cell migration, invasion, and decreased the sensitivity to anti-cancer drug. Furthermore, we found that silencing of β1 integrin abolished Focal adhesion kinese (FAK) mediated cell survival. Overexpression of FAK could restore cisplatin-induced apoptosis in β1 integrin-depleted cells. Consistent to in vitro data, β1 integrin expression was also positively correlated with FAK (p = 0.031) in clinical tissue. More importantly, β1 integrin expression was significantly correlated with patient outcome. In summary, our study indicated that β1 integrin could regulate TNBC cells migration, invasion, drug sensitivity, and be a potential prognostic biomarker in TNBC patient survival. View Full-Text
Keywords: Triple negative breast cancer; β1 integrin; migration; invasion; drug sensitivity Triple negative breast cancer; β1 integrin; migration; invasion; drug sensitivity
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Yin, H.-L.; Wu, C.-C.; Lin, C.-H.; Chai, C.-Y.; Hou, M.-F.; Chang, S.-J.; Tsai, H.-P.; Hung, W.-C.; Pan, M.-R.; Luo, C.-W. β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2016, 17, 1432.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top